Jason Q. Tang

Mr. Jason Q. Tang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GVGianluca Veggiani
Gianluca Veggiani
RVR. Villaseñor
R. Villaseñor
GMG. D. Martyn
G. D. Martyn
JTJason Q. Tang
Jason Q. Tang
MKM. W. Krone
M. W. Krone
SSSachdev Sidhu
Sachdev Sidhu
Histone methylation is an important post-translational modification that plays a crucial role in regulating cellular functions, and its dysregulation is implicated in cancer and developmental defects. Therefore, systematic characterization of histone methylation is necessary to elucidate complex biological processes, identify biomarkers, and ultimately, enable drug discovery. Studying histone methylation relies on the use of antibodies, but these suffer from lot-to-lot variation, are costly, and cannot be used in live cells. Chromatin-modification reader domains are potential affinity reagents for methylated histones, but their application is limited by their modest affinities. We used phage display to identify key residues that greatly enhance the affinities of Cbx chromodomains for methylated histone marks and develop a general strategy for enhancing the affinity of chromodomains of the human Cbx protein family. Our strategy allows us to develop powerful probes for genome-wide binding analysis and live-cell imaging. Furthermore, we use optimized chromodomains to develop extremely potent CRISPR-based repressors for tailored gene silencing. Our results highlight the power of engineered chromodomains for analyzing protein interaction networks involving chromatin and represent a modular platform for efficient gene silencing.

21 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
JTJason Q. Tang
Jason Q. Tang
MMMary M. Marchand
Mary M. Marchand
GVGianluca Veggiani
Gianluca Veggiani
Protein turnover, a highly regulated process governed by the ubiquitin–proteasome system (UPS), is essential for maintaining cellular homeostasis. Dysregulation of the UPS has been implicated in various diseases, including viral infections and cancer, making the proteins in the UPS attractive targets for therapeutic intervention. However, the functional and structural redundancies of UPS enzymes present challenges in identifying precise drug targets and achieving target selectivity. Consequently, only 26S proteasome inhibitors have successfully advanced to clinical use thus far. To overcome these obstacles, engineered peptides and proteins, particularly engineered ubiquitin, have emerged as promising alternatives. In this review, we examine the impact of engineered ubiquitin on UPS and non-UPS proteins, as well as on viral enzymes. Furthermore, we explore their potential to guide the development of small molecules targeting novel surfaces, thereby expanding the range of druggable targets.

30 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GVGianluca Veggiani
Gianluca Veggiani
RVR. Villaseñor
R. Villaseñor
GMG. D. Martyn
G. D. Martyn
JTJason Q. Tang
Jason Q. Tang
MKM. W. Krone
M. W. Krone
SSSachdev Sidhu
Sachdev Sidhu